



**FierceBiotech names *immatics* biotechnologies one of the
“Fierce 15” biotech companies of 2007**

***immatics* is “fierce,” on leading edge of biotech**

Tuebingen, Germany, June 6, 2007. *immatics* biotechnologies announced today that it has been named to the annual FierceBiotech “Fierce 15” list, designating it as one of the top biotech companies of 2007. The editors of FierceBiotech evaluated hundreds of privately held firms on the basis of their company vision, revenue potential, deal quality, technological strength, partnerships, and competitive market position. *immatics* biotechnologies was determined to be one of the “fiercest,” as demonstrated by their creativity and innovations in the industry.

An internationally recognized daily newsletter reaching more than 56,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick, authoritative briefing on the day’s top stories, with a special focus on drug discovery and clinical trials. “Immunotherapeutics is becoming one of the hottest fields in cancer research, and *immatics* can play a leading role in Europe,” said John Carroll, Editor of FierceBiotech.

“Being selected as a member of the ‘Fierce 15’ is an honor that highlights *immatics*’ potential for making a significant impact on the biotech market as well as for providing more effective and safe immunotherapeutics for cancer patients,” said *immatics* COO Niels Emmerich. He and CSO Harpreet Singh co-founded the Company in the year 2000 with the objective of developing effective cancer-fighting immunotherapeutics on the basis of multiple tumor-associated peptides. Since then, *immatics* has raised more than €54 million (US\$ 73 million) in venture capital. Within just the next few weeks, the clinical development program, which is headed up by *immatics* CMO Juergen Frisch, will advance to another milestone for *immatics* – the start of an international multi-center Phase 2 trial of IMA901, an immunotherapeutic that is designed to activate immune cells against renal cancer. *immatics* will also be utilizing its funding to initiate a second proof-of-concept trial of a further product, IMA910 for the treatment of colorectal cancer, and will further expand its pre-clinical pipeline of peptide-based products across several cancer indications.

30 The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. The complete list of ‘Fierce 15’ companies is available in today’s issue of FierceBiotech and on the FierceBiotech Web site at www.fiercebiotech.com.

35 **About FierceMarkets**

FierceMarkets is a digital business media company serving vertical markets with email newsletters, web sites, and live events. Based in Washington, DC, FierceMarkets publications reach more than 450,000 executives in over 100 countries every business day. Current publications include DailyTechRag (<http://www.dailytechrag.com>),
40 FierceBioResearcher (<http://www.fiercebioreseracher.com>), FierceBiotech (<http://www.fiercebiotech.com>), FierceBioResearcher (<http://www.fiercebioreseracher.com>), FierceCIO (<http://www.fiercecio.com>), FierceDeveloper (<http://www.fiercedeveloper.com>), FierceFinance (<http://www.fiercefinance.com>), FierceGameBiz (<http://www.fiercgamebiz.com>), FierceHealthcare (<http://www.fiercehealthcare.com>),
45 FierceHealthIT (<http://www.fiercehealthit.com>), FierceIPTV (<http://www.fierceptv.com>), FierceMobileContent (<http://www.fiercemobilecontent.com>), FierceSarbox (<http://www.fiercesarbox.com>), FierceVoIP (<http://www.fiercevoip.com>), FierceWiFi (<http://www.fiercewifi.com>), FierceWireless (<http://www.fiercewireless.com>), and IT-Wireless (<http://www.it-wireless.com>), and The Business VoIP Report (<http://www.businessvoipreport.com>).

About *immatics*

immatics (www.immatics.com) is an independent biopharmaceutical company that is dedicated to the development of innovative peptide-based therapeutic vaccines for cancer therapy. The product candidates from *immatics* are based upon tumor-associated peptides (TUMAPs) that specifically stimulate the immune system against cancer cells. In September 2006 – barely three years after the launch of early preclinical development – the company successfully concluded an international clinical Phase 1 study on its IMA901 product candidate for combating renal cancer. Further peptide-based cancer immunotherapeutics are presently undergoing preclinical development and will serve as the basis for a rapidly expanding product pipeline. Formed in the year 2000 as a spin-off from the Institute of Immunology at the University of Tuebingen, *immatics* today employs a staff of more than 40 people. Since its founding, *immatics* has been able to raise €54 million (US\$ 73 million) from venture capital firms in two rounds of funding. The first round, involving €14 million, was
65 concluded in the spring of 2004. The second round, involving €40 million – the largest private round of financing for a German biotech company since 2001 – was concluded in February 2007.

70 **For further information**

Heather Cox
FierceMarkets, Inc.
1319 F St., NW
Washington, DC 20004

Harpreet Singh
immatics biotechnologies GmbH
Paul-Ehrlich-Str. 15
72076 Tuebingen, Germany

+1-202-628-8778 x13
heather@fiercemarkets.com

+49-7071-565125-12
singh@immatics.com